Clinical outcomes of sequential androgen receptor pathway inhibitors (ARPIs) versus novel therapies in metastatic castration-resistant prostate cancer after progression on second-generation ARPIs: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results